Determination of acid α-glucosidase protein: Evaluation as a screening marker for Pompe disease and other lysosomal storage disorders

K. Umapathysivam, A. M. Whittle, E. Ranieri, C. Bindloss, E. M. Ravenscroft, O. P. Van Diggelen, J. J. Hopwood, P. J. Meikle

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Background: In recent years, there have been significant advances in the development of enzyme replacement and other therapies for lysosomal storage disorders (LSDs). Early diagnosis, before the onset of irreversible pathology, has been demonstrated to be critical for maximum efficacy of current and proposed therapies. In the absence of a family history, the presymptomatic detection of these disorders ideally can be achieved through a newborn screening program. One approach to the development of such a program is the identification of suitable screening markers. In this study, the acid α-glucosidase protein was evaluated as a marker protein for Pompe disease and potentially for other LSDs. Methods: Two sensitive immunoquantification assays for the measurement of total (precursor and mature) and mature forms of acid α-glucosidase protein were used to determine the concentrations in plasma and dried blood spots from control and LSD-affected individuals. Results: In the majority of LSDs, no significant increases above control values were observed. However, individuals with Pompe disease showed a marked decrease in acid α-glucosidase protein in both plasma and whole blood compared with unaffected controls. For plasma samples, this assay gave a sensitivity of 95% with a specificity of 100%. For blood spot samples, the sensitivity was 82% with a specificity of 100%. Conclusions: This study demonstrates that it is possible to screen for Pompe disease by screening the concentration of total acid α-glucosidase in plasma or dried blood spots. (C) 2000 American Association for Clinical Chemistry.

LanguageEnglish
Pages1318-1325
Number of pages8
JournalClinical Chemistry
Volume46
Issue number9
Publication statusPublished - 26 Sep 2000
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Umapathysivam, K., Whittle, A. M., Ranieri, E., Bindloss, C., Ravenscroft, E. M., Van Diggelen, O. P., ... Meikle, P. J. (2000). Determination of acid α-glucosidase protein: Evaluation as a screening marker for Pompe disease and other lysosomal storage disorders. Clinical Chemistry, 46(9), 1318-1325.
Umapathysivam, K. ; Whittle, A. M. ; Ranieri, E. ; Bindloss, C. ; Ravenscroft, E. M. ; Van Diggelen, O. P. ; Hopwood, J. J. ; Meikle, P. J. / Determination of acid α-glucosidase protein : Evaluation as a screening marker for Pompe disease and other lysosomal storage disorders. In: Clinical Chemistry. 2000 ; Vol. 46, No. 9. pp. 1318-1325.
@article{c55f5ed52e1c48d9b300f0851d1e0d76,
title = "Determination of acid α-glucosidase protein: Evaluation as a screening marker for Pompe disease and other lysosomal storage disorders",
abstract = "Background: In recent years, there have been significant advances in the development of enzyme replacement and other therapies for lysosomal storage disorders (LSDs). Early diagnosis, before the onset of irreversible pathology, has been demonstrated to be critical for maximum efficacy of current and proposed therapies. In the absence of a family history, the presymptomatic detection of these disorders ideally can be achieved through a newborn screening program. One approach to the development of such a program is the identification of suitable screening markers. In this study, the acid α-glucosidase protein was evaluated as a marker protein for Pompe disease and potentially for other LSDs. Methods: Two sensitive immunoquantification assays for the measurement of total (precursor and mature) and mature forms of acid α-glucosidase protein were used to determine the concentrations in plasma and dried blood spots from control and LSD-affected individuals. Results: In the majority of LSDs, no significant increases above control values were observed. However, individuals with Pompe disease showed a marked decrease in acid α-glucosidase protein in both plasma and whole blood compared with unaffected controls. For plasma samples, this assay gave a sensitivity of 95{\%} with a specificity of 100{\%}. For blood spot samples, the sensitivity was 82{\%} with a specificity of 100{\%}. Conclusions: This study demonstrates that it is possible to screen for Pompe disease by screening the concentration of total acid α-glucosidase in plasma or dried blood spots. (C) 2000 American Association for Clinical Chemistry.",
author = "K. Umapathysivam and Whittle, {A. M.} and E. Ranieri and C. Bindloss and Ravenscroft, {E. M.} and {Van Diggelen}, {O. P.} and Hopwood, {J. J.} and Meikle, {P. J.}",
year = "2000",
month = "9",
day = "26",
language = "English",
volume = "46",
pages = "1318--1325",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "9",

}

Umapathysivam, K, Whittle, AM, Ranieri, E, Bindloss, C, Ravenscroft, EM, Van Diggelen, OP, Hopwood, JJ & Meikle, PJ 2000, 'Determination of acid α-glucosidase protein: Evaluation as a screening marker for Pompe disease and other lysosomal storage disorders', Clinical Chemistry, vol. 46, no. 9, pp. 1318-1325.

Determination of acid α-glucosidase protein : Evaluation as a screening marker for Pompe disease and other lysosomal storage disorders. / Umapathysivam, K.; Whittle, A. M.; Ranieri, E.; Bindloss, C.; Ravenscroft, E. M.; Van Diggelen, O. P.; Hopwood, J. J.; Meikle, P. J.

In: Clinical Chemistry, Vol. 46, No. 9, 26.09.2000, p. 1318-1325.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Determination of acid α-glucosidase protein

T2 - Clinical Chemistry

AU - Umapathysivam, K.

AU - Whittle, A. M.

AU - Ranieri, E.

AU - Bindloss, C.

AU - Ravenscroft, E. M.

AU - Van Diggelen, O. P.

AU - Hopwood, J. J.

AU - Meikle, P. J.

PY - 2000/9/26

Y1 - 2000/9/26

N2 - Background: In recent years, there have been significant advances in the development of enzyme replacement and other therapies for lysosomal storage disorders (LSDs). Early diagnosis, before the onset of irreversible pathology, has been demonstrated to be critical for maximum efficacy of current and proposed therapies. In the absence of a family history, the presymptomatic detection of these disorders ideally can be achieved through a newborn screening program. One approach to the development of such a program is the identification of suitable screening markers. In this study, the acid α-glucosidase protein was evaluated as a marker protein for Pompe disease and potentially for other LSDs. Methods: Two sensitive immunoquantification assays for the measurement of total (precursor and mature) and mature forms of acid α-glucosidase protein were used to determine the concentrations in plasma and dried blood spots from control and LSD-affected individuals. Results: In the majority of LSDs, no significant increases above control values were observed. However, individuals with Pompe disease showed a marked decrease in acid α-glucosidase protein in both plasma and whole blood compared with unaffected controls. For plasma samples, this assay gave a sensitivity of 95% with a specificity of 100%. For blood spot samples, the sensitivity was 82% with a specificity of 100%. Conclusions: This study demonstrates that it is possible to screen for Pompe disease by screening the concentration of total acid α-glucosidase in plasma or dried blood spots. (C) 2000 American Association for Clinical Chemistry.

AB - Background: In recent years, there have been significant advances in the development of enzyme replacement and other therapies for lysosomal storage disorders (LSDs). Early diagnosis, before the onset of irreversible pathology, has been demonstrated to be critical for maximum efficacy of current and proposed therapies. In the absence of a family history, the presymptomatic detection of these disorders ideally can be achieved through a newborn screening program. One approach to the development of such a program is the identification of suitable screening markers. In this study, the acid α-glucosidase protein was evaluated as a marker protein for Pompe disease and potentially for other LSDs. Methods: Two sensitive immunoquantification assays for the measurement of total (precursor and mature) and mature forms of acid α-glucosidase protein were used to determine the concentrations in plasma and dried blood spots from control and LSD-affected individuals. Results: In the majority of LSDs, no significant increases above control values were observed. However, individuals with Pompe disease showed a marked decrease in acid α-glucosidase protein in both plasma and whole blood compared with unaffected controls. For plasma samples, this assay gave a sensitivity of 95% with a specificity of 100%. For blood spot samples, the sensitivity was 82% with a specificity of 100%. Conclusions: This study demonstrates that it is possible to screen for Pompe disease by screening the concentration of total acid α-glucosidase in plasma or dried blood spots. (C) 2000 American Association for Clinical Chemistry.

UR - http://www.scopus.com/inward/record.url?scp=0033821427&partnerID=8YFLogxK

M3 - Article

VL - 46

SP - 1318

EP - 1325

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 9

ER -

Umapathysivam K, Whittle AM, Ranieri E, Bindloss C, Ravenscroft EM, Van Diggelen OP et al. Determination of acid α-glucosidase protein: Evaluation as a screening marker for Pompe disease and other lysosomal storage disorders. Clinical Chemistry. 2000 Sep 26;46(9):1318-1325.